Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating a new combination of medicines, DSP107 and atezolizumab, compared to an existing treatment, fruquintinib, for adults with advanced microsatellite stable MSS colorectal cancer. This Phase 2b study focuses on patients whose cancer has progressed or who cannot tolerate standard therapies. The study aims to assess whether the new combination improves patient outcomes while monitoring safety and how the body processes these treatments. Participants will be randomly assigned to one of two groups. One group receives DSP107 intravenously on Days 1, 8, and 15, plus atezolizumab intravenously on Day 1 of each 28-day cycle. The other group takes fruquintinib orally once daily for 21 days, followed by 7 days off, in 28-day cycles. The treatment period can last up to 24 cycles, with adjustments made based on tolerance. After treatment, a safety follow-up of up to 90 days will occur, followed by long-term follow-up for up to five years. During the study, participants will have regular assessments including evaluations of overall survival, adverse events, heart function via ECG, blood pressure, pulse rate, quality of life, and immune response to DSP107. Participants keep dosing diaries if taking fruquintinib. The study includes screening lasting up to 28 days before treatment starts. Total participation time depends on treatment response and tolerability, with ongoing monitoring throughout and after the treatment phase.
Actively Recruiting
Researchers are evaluating the safety and preliminary effectiveness of a drug called DB-1311 combined with BNT327 or DB-1305 in adults with various advanced or metastatic solid tumors. This phase II, open-label study includes participants with types of cancer such as hepatocellular carcinoma, cervical cancer, melanoma, head and neck squamous cell carcinoma, ovarian cancer resistant or sensitive to platinum, non-small cell lung cancer, pancreatic ductal carcinoma, breast cancer, colorectal cancer, and metastatic castration-resistant prostate cancer. The purpose is to find suitable doses and assess treatment responses in these targeted groups. Participants receive intravenous doses of DB-1311 combined with either BNT327 or DB-1305. The trial has two parts Part 1 focuses on dose escalation to establish recommended doses, and Part 2 evaluates treatment effects at these doses across different cancer types. Multiple study arms correspond to different combinations and cancer subtypes, with ongoing treatment until study end or discontinuation. The study is conducted at multiple centers and is randomized but open-label. During the study, participants undergo assessments including tumor measurements based on RECIST criteria, safety monitoring for adverse events, and laboratory tests measuring drug levels and immune responses. Researchers track outcomes like dose limiting toxicities, objective response rates, duration of response, overall survival, progression-free survival, and specific cancer markers such as cancer antigen 125 and prostate-specific antigen. The study may last up to 72 months, with long-term follow-up and safety evaluations throughout.
Actively Recruiting
Researchers are conducting a Phase 12a clinical trial to evaluate DB-1419, a drug given by intravenous injection, for people with advanced or metastatic solid tumors that have relapsed, progressed, or have no standard treatment options. This open-label, multicenter study aims to assess the safety, tolerability, how the drug is processed in the body, and early signs of antitumor activity in participants. The trial is sponsored by DualityBio Inc. and includes adults aged 18 and older with measurable tumors or bone-only disease in some cases. Participants receive DB-1419 at various dose levels ranging from Dose Level 1 up to Dose Level 9. The study is non-randomized and includes dose escalation and dose expansion phases to determine the maximum tolerated dose and recommended dose for further study. The drug is administered by vein injection, and dosing cycles last either 14 or 21 days, with up to 8 cycles monitored for pharmacokinetics and immune response markers. During the study, participants undergo tumor assessments using RECIST v1.1 criteria to measure response, as well as monitoring for adverse events and serious adverse events for up to 90 days after the last dose or before new cancer treatment begins. Additional tests include cardiac function evaluation, blood tests for drug levels and antibodies, and physical exams. The study tracks progression-free survival, overall survival, and other safety and efficacy outcomes for approximately 12 months. Participants must provide consent and comply with study procedures throughout this period.